EPCAM and neoplasm: Interestingly, additional anti-PD-1 treatment did not increase intratumoral EpCAM/GFPCAR T-cell density or anti-tumor efficacy, resulting in a similar growth pattern compared to animals receiving the IgG isotype control antibody (Figs. 2b, e and 3b, c, e, f).